Form 4: Stoke Therapeutics GC Sells Shares Under 10b5-1 Plan

Stoke Therapeutics' General Counsel, Jonathan Allan, executed a pre-planned sale of 10,000 common shares after exercising stock options.

Summary

• Jonathan Allan, General Counsel & Corporate Secretary of Stoke Therapeutics, Inc. (STOK), reported transactions on October 3, 2025.
• Allan exercised options to acquire 10,000 shares of common stock at an exercise price of $9.15 per share.
• Concurrently, he sold 10,000 shares of common stock at a weighted average price of $25.065 per share.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024.
• Following these transactions, Allan directly beneficially owns 11,831 shares of common stock and 34,800 stock options.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale could be seen negatively, the execution under a Rule 10b5-1 plan indicates a pre-scheduled transaction for personal financial planning rather than a reaction to new company-specific information. The insider also realized a substantial profit, which is a positive for the individual.

Positives

• The reporting person realized a significant profit from the exercise of options and subsequent sale of shares, indicating a favorable spread between the exercise price ($9.15) and the weighted average sale price ($25.065).

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived by the market as a lack of confidence, though the Rule 10b5-1 plan mitigates this interpretation.

Risks

• Potential negative market perception if investors misinterpret the insider sale as a signal of declining company prospects, despite the pre-arranged nature of the transaction.

Future Outlook

The filing does not provide specific forward-looking statements or guidance regarding the company's future performance or strategic direction, focusing solely on an insider's equity transactions.

Management Comments

• The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2024.
• The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.20, inclusive.

Industry Context

Insider transactions, particularly those executed under Rule 10b5-1 plans, are common in the biotechnology sector as a means for executives to manage their equity holdings for diversification or liquidity while adhering to insider trading regulations. These pre-arranged plans typically reduce the signal of immediate market sentiment compared to unplanned sales.

Comparison to Industry Standards

• Not applicable. This filing reports an individual insider transaction, which does not lend itself to direct comparison with industry-wide financial benchmarks or project results. The transaction itself is standard practice for executive compensation and liquidity management within public companies.

Stakeholder Impact

• Shareholders may observe the insider sale and interpret it, though the 10b5-1 plan suggests it is not a signal of immediate company distress. The profit realized by the insider could be viewed positively as a reward for performance.

Next Steps

• The filing does not mention any specific future actions, events, or milestones for the company or the reporting person beyond the ongoing vesting schedule of remaining options.

Key Dates

Recommendation

While the General Counsel sold a significant number of shares, the transaction was executed under a pre-arranged Rule 10b5-1 plan, which typically signals a planned liquidity event rather than a reaction to new, adverse company information. The insider also realized a substantial profit, which is a positive for the individual. Without additional company-specific news or financial updates, this Form 4 alone does not provide a strong enough signal to warrant a 'buy' or 'sell' recommendation, thus a 'hold' is appropriate as investors await further operational or financial disclosures.

Keywords

Stoke Therapeutics, STOK, Jonathan Allan, Form 4, insider trading, stock options, share sale, 10b5-1 plan, executive compensation